Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE
Deciphera Pharmaceuticals, LLC
Michael C Heinrich; Jean-Yves Blay; Hans Gelderblom; Suzanne George; Patrick Schöffski; Margaret von Mehren; John R Zalcberg; Robin L Jones; Yoon-Koo Kang; Albiruni Abdul Razak; Jonathan Trent; Steven Attia; Axel Le Cesne; Kjetil Boye; David Goldstein; César Sánchez; Brittany L Siontis; Paulina Cox; Erika Davis; Matthew L Sherman; Rodrigo Ruiz-Soto; Sebastian Bauer